EW - Edwards Lifesciences Corporation

NYSE - NYSE Delayed Price. Currency in USD
218.81
+0.31 (+0.14%)
At close: 4:00PM EDT
Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close218.50
Open218.96
Bid218.62 x 1400
Ask219.55 x 1200
Day's Range215.05 - 219.05
52 Week Range154.52 - 247.64
Volume730,965
Avg. Volume1,642,610
Market Cap46.388B
Beta (5Y Monthly)0.85
PE Ratio (TTM)41.92
EPS (TTM)5.22
Earnings DateJul 21, 2020 - Jul 27, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est242.68
  • Moody's

    Edwards Lifesciences Corporation -- Moody's announces completion of a periodic review of ratings of Edwards Lifesciences Corporation

    Moody's Investors Service ("Moody's") has completed a periodic review of the ratings of Edwards Lifesciences Corporation and other ratings that are associated with the same analytical unit. The review was conducted through a portfolio review in which Moody's reassessed the appropriateness of the ratings in the context of the relevant principal methodology(ies), recent developments, and a comparison of the financial and operating profile to similarly rated peers.

  • Wedgewood Partners Cuts Fastenal, Alphabet, Visa
    GuruFocus.com

    Wedgewood Partners Cuts Fastenal, Alphabet, Visa

    Firm's largest sales of the 1st quarter Continue reading...

  • Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair
    PR Newswire

    Edwards PASCAL Transcatheter Valve Repair System Receives European Approval For Tricuspid Repair

    Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that it has received CE Mark for the Edwards PASCAL transcatheter valve repair system for the treatment of European patients with tricuspid regurgitation (TR).

  • Thomson Reuters StreetEvents

    Edited Transcript of EW earnings conference call or presentation 23-Apr-20 9:00pm GMT

    Q1 2020 Edwards Lifesciences Corp Earnings Call

  • Insider Monkey

    Is Edwards Lifesciences (EW) a Great Value Stock Right Now?

    Artisan Mid Cap Fund recently released its Q1 2020 Investor Letter, a copy of which you can download below. The fund posted a return of -11.55% for the quarter (investor class), outperforming their benchmark, the Russell Midcap Index which returned -27.07% in the same quarter. You should check out Artisan Mid Cap Fund’s top 5 […]

  • Edwards Announces Updates From Annual Meeting
    PR Newswire

    Edwards Announces Updates From Annual Meeting

    Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced updates from its annual meeting, in which Edwards' stockholders voted with the board's recommendations on all proxy proposals.

  • Stock Upgrades: Edwards Lifesciences Shows Rising Relative Strength
    Investor's Business Daily

    Stock Upgrades: Edwards Lifesciences Shows Rising Relative Strength

    On Wednesday, Edwards Lifesciences got a positive adjustment to its Relative Strength (RS) Rating, from 79 to 83. When looking for the best stocks to buy and watch, one factor to watch closely is relative price strength. Edwards Lifesciences is working on a consolidation with a 247.74 entry.

  • Edwards Lifesciences Announces May 2020 Investor Conference Schedule
    PR Newswire

    Edwards Lifesciences Announces May 2020 Investor Conference Schedule

    Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, is scheduled to participate in two upcoming investor conferences.

  • Why Edwards Lifesciences Shares Rose 15.3% in April
    Motley Fool

    Why Edwards Lifesciences Shares Rose 15.3% in April

    Edwards Lifesciences (NYSE: EW) shares rose 15.3% in April, according to data provided by S&P Global Market Intelligence. Edwards Lifesciences, like many other companies across industries, fell in March as the coronavirus outbreak deepened in the U.S. With stay-at-home orders issued across the country, investors worried about the impact of the health crisis on businesses' earnings. Transcatheter aortic valve replacement (TAVR) with the Sapien 3 continued to show favorable results for these patients compared with surgery.

  • Were Hedge Funds Right About Edwards Lifesciences Corporation (EW)?
    Insider Monkey

    Were Hedge Funds Right About Edwards Lifesciences Corporation (EW)?

    Coronavirus is probably the 1 concern in investors' minds right now. It should be. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW. We predicted that a US recession is imminent and US stocks will go down by at least 20% in the next 3-6 […]

  • The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences
    Zacks

    The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences

    The Zacks Analyst Blog Highlights: Cisco, Abbott Laboratories, NextEra Energy, Gilead Sciences and Edwards Lifesciences

  • Insider Monkey

    Why Wedgewood Partners is Bullish on Edwards Lifesciences (EW) Stock?

    Wedgewood Partners, a St. Louis, Missouri-based investment management firm, released its Q1 2020 Investor letter – a copy of which is available for download here. Wedgewood Partners returned -16.30% for the first quarter. Meanwhile, the benchmark Russell 1000 Growth Index and the S&P 500 Index lost 14.10% and 19.60%, respectively. In the said letter, Wedgewood Partners […]

  • Top Stock Research Reports for Cisco, Abbott, NextEra & Others
    Zacks

    Top Stock Research Reports for Cisco, Abbott, NextEra & Others

    Top Stock Research Reports for Cisco, Abbott, NextEra & Others

  • Benzinga

    Benzinga Pro's Top 4 Stocks To Watch For Tues., Apr. 28, 2020: BA, FFIV, EW, ATIF

    Today's 4 Stock Ideas: * Boeing (BA) \- An earnings play. The company will report quarterly results Wednesday morning before the market open. * F5 Networks (FFIV) \- A play on strong guidance. With the company's Q2 earnings report issued Monday afternoon, F5 said it expects Q3 EPS of $1.91-$2.13 vs the analyst consensus estimate of $1.84. Sales are expected to be between $555 million and $585 million vs the analyst estimate of $546.9 million. * Edwards Lifesciences (EW) \- A play on patient monitoring. The company said its HemoSphere platform received expanded use indication from Health Canada related to coronavirus patients. * ATIF Holdings (ATIF) \- A play on 5G and AI info distribution. The company on Monday outlined a plan for its platform to integrate data of urban cities.See more from Benzinga * Benzinga Pro's Top 5 Stocks To Watch For Fri., Apr. 24, 2020: GILD, DKNG, FFIV, ADC, SGMS * Benzinga Pro's Top 5 Stocks To Watch For Thurs., Mar. 12, 2020: BA, APT, UBER, APRN, CHFS * Benzinga Pro's Top 5 Stocks To Watch For Mon., Mar. 9, 2020: XOM, GLD, BA, TSLA, SPEX(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • GlobeNewswire

    Edwards’ HemoSphere Platform Receives Expanded Use Indication From Health Canada in Treatment of COVID-19 Patients

    Edwards Lifesciences Corporation (EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today announced that Health Canada approved an expanded indication for use of the HemoSphere advanced monitoring platform in the treatment of COVID-19 patients. This approval was granted following an interim order issued by Health Canada to address the pressing need for medical supplies used in the response to the COVID-19 pandemic. Hemodynamic monitoring refers to the measurement and tracking of different vital signs that help manage blood flow and oxygenation in critically ill patients, like those who are being treated for COVID-19.

  • Dow Jones Erases 200-Point Gain After Coronavirus Stimulus; Intel Dives On Earnings, While Apple Nears New Buy Point
    Investor's Business Daily

    Dow Jones Erases 200-Point Gain After Coronavirus Stimulus; Intel Dives On Earnings, While Apple Nears New Buy Point

    Stocks were mixed early Friday after the passing of the coronavirus stimulus package. Chip giant Intel dove on earnings.

  • The Zacks Analyst Blog Highlights: Intel and Edwards Lifesciences
    Zacks

    The Zacks Analyst Blog Highlights: Intel and Edwards Lifesciences

    The Zacks Analyst Blog Highlights: Intel and Edwards Lifesciences

  • Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View
    Zacks

    Edwards Lifesciences (EW) Beats on Q1 Earnings, Cuts '20 View

    Amid the coronavirus impact on sales, Edwards Lifesciences (EW) witnesses growth in TAVR procedures led by strong therapy adoption across all geographies, particularly in the United States.

  • Intel, Edwards Lifesciences Top Q1 Earnings Estimates
    Zacks

    Intel, Edwards Lifesciences Top Q1 Earnings Estimates

    The chipmaker giant and the MedTech company both outperformed expectations in their Q1 earnings reports.

  • Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates
    Zacks

    Edwards Lifesciences (EW) Q1 Earnings and Revenues Top Estimates

    Edwards Lifesciences (EW) delivered earnings and revenue surprises of 17.05% and 7.64%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

  • Medical Giant Calls For Coronavirus Hit In 2020; But Shares Eye Breakout
    Investor's Business Daily

    Medical Giant Calls For Coronavirus Hit In 2020; But Shares Eye Breakout

    Edwards Lifesciences called for a 2020 slowdown due to the coronavirus pandemic on Thursday, but EW stock popped on a strong first-quarter showing.

  • MarketWatch

    Edwards Lifesciences expects COVID-19 to subtract half a billion dollars from sales, stock gains

    Edwards Lifesciences Corp. announced Thursday that sales and profit for the first quarter came in higher than expectations despite COVID-19, sending shares higher even while detailing the financial hit the pandemic will have on its finances. The medical-device company focused on heart procedures reported first-quarter profit of $310.6 million, or $1.47 a share, on sales of $1.13 billion, up from $993 million a year ago. After adjusting for litigation expenses and other costs, the company reported earnings of $1.51 a share, up from $1.32 a share a year ago. Analysts on average expected adjusted earnings of $1.32 a share on sales of $1.08 billion, according to FactSet. Edwards also revealed that it now expects full-year sales of $4 billion to $4.5 billion, after previously guiding for 2020 revenue of $4.6 billion to $5 billion. Earnings are now expected to be $4.75 to $5.25 a share, down from previous guidance of $6.15 to $6.40 a share. "The company assumes the impact of COVID-19 on sales will be most severe in the second quarter, followed by a gradual recovery in the third quarter, and a fourth quarter that better resembles its original expectations for sales," the company disclosed in its announcement. The stock increased more than 3% in after-hours trading following the announcement, after closing the regular session with a 2.1% gain at $221.04.

  • Edwards Lifesciences Reports First Quarter Results
    PR Newswire

    Edwards Lifesciences Reports First Quarter Results

    Edwards Lifesciences Corporation (NYSE: EW), the global leader in patient-focused innovations for structural heart disease and critical care monitoring, today reported financial results for the quarter ended March 31, 2020.

  • ACCESSWIRE

    Edwards Lifesciences Corp. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / April 23, 2020 / Edwards Lifesciences Corp. (NYSE:EW) will be discussing their earnings results in their 2020 First Quarter Earnings call to be held on April 23, 2020 at 5:00 ...